Jessie J hospitalized for infection following breast cancer surgery
The singer updated fans on her Instagram story Saturday, sharing a photo of an IV in her arm.
Jessie J shares health update on Meniere's disease battle
'How I spent the last 24 hours,' she wrote. '6 weeks post surgery and I was back in the same ward I was after my surgery. Not expected or planned. I had and still have symptoms that pointed towards a blood clot on the lung.'
'IT IS NOT A BLOOD CLOT THANK GOD,' she continued. 'They ran a lot of tests, which ended up showing I have an infection (still trying to figure out what) and a little fluid on my lungs.'
'Finding it hard to breathe in, but I discharged myself last night (I hate being in hospital) and will continue the investigation as an outpatient,' she wrote.
In another post, Jessie J opened up about her health journey, writing, 'I know many people who will have gone through this or similar may agree with me on this or not and that's ok.'
'But I know for me, the true hard journey of this whole thing physically was the day I went into surgery. The recovery physically is far from quick or easy, and mentally it's been the most challenging time for me,' she continued.
The singer, who welcomed her son, Sky Safir Cornish Colman, in May 2023 with boyfriend Chanan Safir Colman, also spoke about the impact of her health on motherhood and her career.
"Especially as a Mum with a toddler and being unable to be the mother I usually am,' she wrote. 'And having to change the plans for my career for this year has been frustrating after working so hard to get to this point and excited to do it all.'
She added, 'But it's life, I know that. And don't get me wrong getting the all clear was and is incredible. But that result didn't speed up or make the recovery from the surgery any easier physically.'
She went on to share that her journey was a reminder 'to myself to slow tf down.'
'This isn't a speedy recovery. And it isn't meant to be,' she said. 'As an adhd Aries fire breathing dragon t rex, I can do it myself, I'm always ok woman. That slow pace has been a hard reality to accept tbh. I love moving and working and being up and active but I can't be right now, and that's what it is.'
'And I am finding the strength in knowing that all can be adjusted to align with a slower pace and the support of my very small inner support circle.YKWYA. Thank you,' she concluded.
Earlier in June, Jessie J revealed she had been diagnosed with "early breast cancer" in an Instagram reel.
"I'm highlighting the word 'early.' Cancer sucks in any form, but I'm holding on to the word 'early,'" she said at the time, adding that she was going to "disappear for a bit to have my surgery," promising that she will "come back with massive t--s and more music."
Later that month, she shared an update post-surgery on June 23, documenting the process with a series of photos on Instagram.
In the caption, she described the post as showing 'some of the honest lows and highs of the last 48 hours.'
'I will always show the good and hard bits of any journey I go through,' she wrote. 'Grateful to my doctor / surgeon and all the nurses who cared for me and all my family / friends who came to visit. 🫂 I am home now, to rest and wait for my results 🤞🏻'
'Still hugging everyone going through something tough right now. We all got this! 🫂🫀🔋,' she added.
Over the years, Jessie J has been open about her health, sharing her experiences with a heart condition she was diagnosed with as a child, as well as a miscarriage in 2021. She has also been diagnosed with an inner-ear disorder, obsessive-compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD).
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
43 minutes ago
- Medscape
NICE Urges Ongoing Support After Obesity Treatment
The National Institute for Health and Care Excellence (NICE) has released updated guidance recommending that healthcare providers offer structured, ongoing support to patients after they complete obesity treatment or stop taking weight-loss medications. This includes regular follow-up care, tailored action plans, and social support to help patients maintain their weight loss and avoid regaining weight. New Drugs Raise Need for Long-Term Support The new quality standard comes as weight-loss medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are being introduced on the NHS. An estimated 240,000 people are set to be offered tirzepatide over the next 3 years. The update addresses a critical gap in current care, noting that many people regain weight after treatment if they lack adequate support, with consequences for both physical and mental health. In England, 29% of adults are living with obesity and 64% of adults are classified as overweight or obese. Obesity-related illnesses are estimated to cost the NHS £11.4 billion a year and have a wider economic impact of £74.3 billion. Ensuring Continuity of Care The guidance stresses that weight management is a long-term process, not a one-time fix. It recommends that healthcare providers ensure continuity of care by monitoring patients for at least 12 months and offering tailored support to help maintain weight loss. This may include NHS Better Health resources and strategies for habit change, as well as practical adjustments at home or at work. The quality standard advocates for a shift from short-term interventions to strategies that foster lasting behavioural changes. It highlights the importance of self-monitoring and connecting patients with broader support networks, such as online communities, family-led initiatives, and local programmes. Guidance Implementation Professor Jonathan Benger, deputy chief executive of NICE, noted that weight management 'doesn't end when medication stops or when someone completes a behavioural programme,' adding that 'people need structured support to maintain the positive changes they've made.' The new guidance replaces three previous standards and reflects the most up-to-date strategies for tackling obesity through the healthcare system. Healthcare services are advised to begin implementing the standard immediately, with resource impact guidance available to assist in local adaptation.
Yahoo
an hour ago
- Yahoo
Experts reveal potential unintended side effect of Ozempic – and whether we should worry
The use of weight-loss jabs in the UK has skyrocketed, with an estimated 1.5 million people using them. Yet drugs like Ozempic and Wegovy don't just help people lose fat, but potentially muscle too, new research has suggested. A study that tested weight loss jabs on mice found that although muscle mass changes less than expected, muscles still get weaker and tissues like the liver also shrink. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. The medications, known as semaglutides, predominantly treat diabetes but are also available on the NHS or via private providers to help adults with a high body mass index (BMI). For example, although Ozempic is used for type 2 diabetes, it is sometimes prescribed off-label as a weight-loss drug. The results of the study, published in the journal Cell Metabolism, revealed Ozempic-induced weight loss decreased muscle mass by about 10 per cent. Most of this lost weight wasn't from skeletal muscles, which surround bones and joints, but instead from other tissues like the liver, which shrank by nearly half. However, because the Ozempic was tested on mice, researchers emphasise that more research is needed to determine whether similar changes to organ size occur in humans and whether those changes come with any risks. 'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' said Dr Ran Hee Choi, research instructor in nutrition and integrative physiology at the University of Utah college of health, and co-first author on the study. In both mice and humans, weight gain and loss can affect the size of organs like the liver without affecting their function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' added Dr Takuya Karasawa, another co-first author on the study. Researchers found some skeletal muscles did shrink by about 6 per cent as the mice lost weight, but not enough to explain the overall muscle loss. However, when someone gains fat, they also tend to gain skeletal muscle. Study authors explain this is because the body needs to work harder to move around. As a result, losing extra fat can lead to a loss of muscle, which will not affect the person's overall quality of life. Researchers also tested the amount of force the mice's muscles exerted and found that some muscle strength decreased as the mice lost weight, even when the size of the muscle stayed roughly the same. This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility. 'The loss of physical function is a strong predictor of not just quality of life but longevity,' added Dr Katsu Funai, professor of nutrition at the University of Utah and the senior author on the study. Dr Funai concluded that further clinical trials of weight loss jabs should check for changes in muscle strength. A spokesperson for Novo Nordisk, which makes Ozempic, said: 'In clinical trial for Wegovy or Ozempic we did not specifically study the medicine's impact on muscle mass. In a sub-study of 140 patients with a BMI of 40 or less, analysis suggested that treatment with Wegovy was accompanied by reductions in both fat and lean body mass, with a greater reduction in fat mass than lean body mass. 'We recommend that any patients experiencing side effects while taking Wegovy or Ozempic contact their healthcare provider.'
Medscape
3 hours ago
- Medscape
Retina Tear Raises Detachment Risk After Cataract Surgery
About 1 in 20 people who have had a laser procedure to patch a retinal tear will have another retinal tear or, worse, a retinal detachment after they have cataract surgery, an analysis of a large electronic health record database has found. The study included 1738 eyes in the Epic Cosmos database that had retinal tears before having cataract surgery. 'The incidence was about 5.3% for a secondary retinal event,' said Basil Williams, MD, a vitreoretinal surgeon at Bascom Palmer Eye Institute in Miami, while presenting study results at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California. That figure is more than five times greater than the overall risk for retinal detachment after cataract surgery, which a 2015 study reported at about 1%. 'Possibly waiting 6 months in between retinal tear and cataract surgery might reduce the risk significantly,' Williams said. The study looked only at retinal tears in eyes that had not had previous cataract surgery, a condition known as phakic retinal tears. Left untreated, a retinal tear could progress to a retinal detachment, in which retinal fluid enters under the retina surface and causes the retina to pull away from the retinal pigment epithelium, the underlying structure from which the retina gets its blood supply. A retinal detachment can lead to vision loss. The study participants who had a previous retina tear were treated with laser before cataract removal, including people who had vitreoretinal surgery at the time of the cataract procedure, Williams said. Men in the study had a 25% greater risk for a retinal event after cataract surgery, and people of Asian ancestry had a greater risk than other patients, possibly because of higher rates of myopia in the Asian population, Williams reported. People who had multiple retinal tears before cataract surgery had almost three times the rate of retinal events than those with one retinal tear, Williams said. Patients who had waited more than 6 months between repair of the retinal tear and cataract surgery had about half the risk for retinal events as those who had cataract surgery sooner. Patients who developed a retinal detachment after cataract surgery were, on average, 64 years old at the initial diagnosis of the tear compared with 67 years for those who had a recurrent retinal tear after cataract surgery. The former group was also 3 years younger when they had cataract surgery: 66 vs 67 years, Williams reported. Mrinali Gupta, MD, a vitreoretinal surgeon at Retina Associates of Orange County in Laguna Hills, California, noted the importance of the time interval between laser surgery to repair retinal tears and cataract surgery. 'The study found that the risk of subsequent retinal break was approximately 40% lower when the time interval between phakic retinal tear treatment and cataract surgery was 6 or more months,' Gupta told Medscape Medical News. Mrinali Gupta, MD A strength of the study was the large number of eyes included in the analysis, Gupta said, but its retrospective nature and reliance on registry data limit the strength of the findings. 'Based upon this study, ophthalmologists may consider referring patients with recently treated phakic retinal tears for a detailed, dilated retinal examination prior to cataract surgery and consider recommending delaying cataract surgery until at least 6 months post-treatment of phakic retinal tears,' she added. Williams reported having financial relationships with DORC International and Alcon. Gupta reported having financial relationships with Carl Zeiss and Alcon.
